 "Cadila Healthcare hits record high on USFDA nod for Clonidine Hcl injection")
Cadila Healthcare is trading higher by 2% at Rs 1,019, extending its yesterday’s nearly 5% rally on the BSE, after the company said it has received the final approval from the US FDA to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices, indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone, reports suggest.
"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a statement.
The stock opened at Rs 1,005 and touched a record high of Rs 1,020 on the NSE. A combined 66,600 shares changed hands on the counter so far on the NSE and BSE.
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices, indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone, reports suggest.
"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a statement.
The stock opened at Rs 1,005 and touched a record high of Rs 1,020 on the NSE. A combined 66,600 shares changed hands on the counter so far on the NSE and BSE.